TrialLupus science & medicine2025

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial.

Marta Mosca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.